Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-PP-F11N
- Development stage
- Unknown
- Lead developer
- Paul Scherrer Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
`[177Lu]Lu-PP-F11N` is a peptide receptor radionuclide therapy (PRRT) agent consisting of the minigastrin analogue PP-F11N conjugated to the chelator DOTA and radiolabeled with the beta-emitting radioisotope lutetium-177 (177Lu). It specifically targets the cholecystokinin B receptor (CCKBR, also known as CCK2R), which is highly overexpressed in medullary thyroid carcinoma (MTC) and other neuroendocrine tumors. Upon binding to CCKBR, the radiopharmaceutical is internalized, delivering localized cytotoxic beta radiation to the tumor cells, leading to DNA damage and cell death. It is being developed by Yukon Biosciences, a spin-off of the Paul Scherrer Institute, in collaboration with University Hospital Basel, and is currently in Phase 1 clinical development for the treatment of advanced medullary thyroid carcinoma and other CCKBR-expressing neuroendocrine tumors.
- Other names
- 177Lu-DOTA-PP-F11N177Lu-PP-F11Nlutetium (177Lu) PP-F11Nlutetium Lu 177 PP-F11Nlutetium-177-labeled minigastrin analogue [177Lu]Lu-PP-F11N
02
Targets
CCK2R (Cholecystokinin 2 Receptor)
Beyond the preview
Go deeper on [177Lu]Lu-PP-F11N.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-PP-F11N.